Patient Characteristics and Outcomes of Relapsed/ Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Oncology research and treatment, Erscheinungsjahr: 2020, Jahrgang: 43, Heft: 9, Seiten: 449-459, ISSN: 2296-5270
- Ereignis
-
Veröffentlichung
- (wo)
-
Leipzig
- (wer)
-
Universitätsbibliothek Leipzig
- (wann)
-
2023
- Urheber
-
Steinmetz, H. Tilmann
Singh, Moushmi
Lebioda, Andrea
Gonzalez-McQuire, Sebastian
Rieth, Achim
Schoehl, Martina
Poenisch, Wolfram
- URN
-
urn:nbn:de:bsz:15-qucosa2-836451
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:42 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Steinmetz, H. Tilmann
- Singh, Moushmi
- Lebioda, Andrea
- Gonzalez-McQuire, Sebastian
- Rieth, Achim
- Schoehl, Martina
- Poenisch, Wolfram
- Universitätsbibliothek Leipzig
Entstanden
- 2023
Ähnliche Objekte (12)
Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Sorafenib in patients with refractory or recurrent multiple myeloma
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma
Efficacy of dose-reduced Ienalidomide in patients with refractory or recurrent multiple myeloma
Functional analysis of oncogenic lesions in multiple myeloma with potential significance for refractory disease
A GRP78-directed monoclonal antibody recaptures response in refractory multiple myeloma with extramedullary involvement
Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Genetic alterations in members of the proteasome 26S subunit, AAA-ATPase (PSMC) gene family in the light of proteasome inhibitor resistance in multiple myeloma
Adrenal insufficiency in patients with corticosteroid-refractory cerebral radiation necrosis treated with bevacizumab
Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Sorafenib in patients with refractory or recurrent multiple myeloma
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma
Efficacy of dose-reduced Ienalidomide in patients with refractory or recurrent multiple myeloma
Functional analysis of oncogenic lesions in multiple myeloma with potential significance for refractory disease
A GRP78-directed monoclonal antibody recaptures response in refractory multiple myeloma with extramedullary involvement
Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Genetic alterations in members of the proteasome 26S subunit, AAA-ATPase (PSMC) gene family in the light of proteasome inhibitor resistance in multiple myeloma
Adrenal insufficiency in patients with corticosteroid-refractory cerebral radiation necrosis treated with bevacizumab
Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Sorafenib in patients with refractory or recurrent multiple myeloma
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma
Efficacy of dose-reduced Ienalidomide in patients with refractory or recurrent multiple myeloma
Functional analysis of oncogenic lesions in multiple myeloma with potential significance for refractory disease
A GRP78-directed monoclonal antibody recaptures response in refractory multiple myeloma with extramedullary involvement
Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Genetic alterations in members of the proteasome 26S subunit, AAA-ATPase (PSMC) gene family in the light of proteasome inhibitor resistance in multiple myeloma